Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer

NCT: NCT05917860 · ACTIVE_NOT_RECRUITING

NCT IDNCT05917860
StatusACTIVE_NOT_RECRUITING
Start Date2023-07-18
Completion2030-01-31
SponsorTurku University Hospital (OTHER_GOV)
First posted
Last updated

Brief Summary

Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound. This clinical trial explores if adding drug therapy with Degarelix before TULSA has the potential to improve further the effectiveness of TULSA in the treatment of localized prostate cancer, especially for patients with more aggressive diseases.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑